Yearly Archive

Yearly Archives: 2014

August 19, 2014 no comments

After NICE is it time for NASTY? National Academy for the Study of Things that harm You

The United Kingdom’s National Institute for Clinical Excellence (NICE) has proven its worth as an independent arbiter of value-for-money when it comes to medical interventions.  People may question the details of the methodology they employ to compare effectiveness of drugs and procedures, but few doubt the principle of its existence.

Unfortunately, there is no equivalent framework for assessing public health interventions.  A swathe of unreliable cross0-secvtional studies have highlighted potential harms from a diverse array of sources, but particularly various components of our diet.  A vocal minority is calling for action to limit these perceived “harms”.  But how real is the risk?  Even where the risk is proven, how much of a contributor to our overall health are these factors? There is a very real risk governments will start to intervene (through legislation or tax measures to disincentives certain behaviours) on the basis of public perception rather than a quantitive, rational and transparent assessment of the costs and benefits of such interventions.

The solution, according to DrugBaron, is to adopt the NICE methodology to estimate value-for-money of proposed public health interventions, in exactly the same way we do for medical interventions.  This would be the mission of the National Academy for the Study of Things that harm You (NASTY).


July 8, 2014 comments

Twenty six of the best candidate protein biomarkers have no ability to predict Alzheimer’s Disease

DrugBaron woke up this morning to the latest …

October 2, 2013 no comments

PheWAS – the tool that’s revolutionizing drug development that you’ve likely never heard of

Late-stage attrition kills returns on pharma R&D investment.  …

June 24, 2013 no comments

Positive publication bias IS harmful

DrugBaron was intrigued to see a paper published …

November 27, 2012 no comments

Healthcare-omics: why we should close down every angiography suite and hand out free statins to everyone

Billions are spent discovering new medicines every year …

March 13, 2012 no comments

Drugging the apolioprotein E pathway – the starters gun has sounded

It can take years or even decades to …

January 23, 2012 no comments

Merck’s $800M bet on Sir Austin Bradford Hill

Why Merck’s CETP Inhibitor programme is such a …


Yearly Archive